CERS

$2.90+$0.13 (+4.80%)live

Compare

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institution

Market cap

$546.1M

202M shares

52-week range

$1.15 – $3.47

75% from low

Sector

SURGICAL & MEDICAL INSTRUMENTS & APPARATUS

Exchange

NASDAQ

Change$-3.06

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$254M	+9.8%	$-0.04	$-0.04–$-0.04	—	1
2027	$274M	+7.8%	$-0.01	$-0.01–$-0.01	—	1
2028	$310M	+13.3%	$0.06	$0.06–$0.06	48.3×	1

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 6 of the last 8 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-07-30	$-0.01	$-0.01	+25.0%
2026-04-30	$-0.03	$-0.01	+66.7%
2026-03-02	$-0.01	$-0.01	+0.0%
2025-11-06	$-0.02	$-0.00	+99.5%
2025-08-05	$-0.02	$-0.03	-50.0%
2025-05-01	$-0.05	$-0.04	+20.0%
2025-02-20	$-0.01	$-0.01	+0.0%
2024-10-30	$-0.01	$-0.02	-33.3%

DCF fair valuemodel estimate

Intrinsic value

$2.82

Price

$2.90

Implied downside

-3%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
CERSCerus Corporation	$2.84	+4.80%	$572M	—
CVRXCVRx, Inc.	$2.94	+7.69%	$78M	—
MASS908 Devices Inc.	$10.11	+0.90%	$415M	—
NPCENeuroPace, Inc.	$14.51	-0.34%	$495M	—
QTRXQuanterix Corporation	$2.86	-2.39%

Cerus Corp

Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety, and generates revenue from the same.

www.cerus.com

Employees: 345
IPO / List date: Jan 31, 1997
HQ: CONCORD, CA

Held by traders on TradeandTell

No one on the platform currently holds CERS.

Super investors & insiders

Institutions holding (13F)

Institution	Shares	Reported
Renaissance Technologiesas of 2026-03-31	578,900	$1.1M

Insider activity (SEC Form 4)

Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded CERS yet.

$CERS chatter on StockTwits

John McGuire@healthcareguruBullish16h
$CERS I want this>$3 by tmrw close…DO YOUR JOB! 🦾🔥
View on StockTwits ↗
Cameron Brodie@Violenteer18h
$CERS Bull case is getting stronger.. Growing revenue. Raised guidance. Multiple catalysts ahead. The stock got crushed. The business didn't. $CERS looks like a broken stock, not a broken company. I'm bullish.
View on StockTwits ↗
Dan Sedon@Acamus18h
$CERS I want to believe in you, baby, but I've been hurt before and you keep saying you'll change or this time will be different, but it never is.
View on StockTwits ↗
Anders Jacobsen@Spooky221d
$CERS @OldManLogan You were totally right back then. It might not continue like that as fast as it did the last days, but another move upward in anticipation of the readout is inevitable imo.
View on StockTwits ↗
John McGuire@healthcareguruBullish1d
$CERS RBC trial readout in 4Q…can be major catalyst on top of already consistently beating/raising guidance…see you at $5+. 🦾🔥 $XLV $XBI
View on StockTwits ↗
Logan Howlett@OldManLogan1d
$CERS 8 days ahead of schedule...
View on StockTwits ↗
Logan Howlett@OldManLogan1d
$CERS Low twos was a complete gift. Stock still undervalued relative to longterm potential... especially with the RBC program upcoming...
View on StockTwits ↗
Sid Jack@sk7777777Bullish2d
$CERS Call me when it hit 4. Then I want to start keeping watch. Thanks
View on StockTwits ↗
Sid Jack@sk7777777Bullish2d
$CERS Set it and forget it.
View on StockTwits ↗
Sid Jack@sk7777777Bullish2d
$CERS I believe these are great reasons to be here and we have a gap to fill on the daily at 2.84ish and continue past 3. Cathie Wood recently purchased 87,357 shares of Cerus Corp (CERS) for ARK InvestStrong Fundamental Momentum and currently holds roughly 19.2 million shares. In its recent Q2 2026 earnings report, Cerus reported that revenue grew 10% year-over-year to $63.3 million. Raised Guidance: Management felt confident enough to raise full-year 2026 product revenue guidance to a range of $229 million to $231 million. Improved Financial Health: The company achieved its eighth consecutive quarter of positive adjusted EBITDA and successfully refinanced its debt, cutting annual interest expenses by up to $3.5 million. Catalysts on the Horizon: Cerus recently submitted its INT200 platelet application to the FDA, with a potential approval window opening in the first half of 2027. Recent upgrade from BTIG to Buy on 5/1/2026.
View on StockTwits ↗
carmine marinelli@cambo_retire3d
$CERS retesting the 100sma-let’s fill that gap!
View on StockTwits ↗
carmine marinelli@cambo_retire5d
$CERS yesterday was a lousy close-up all day as high as 2.42 then sells off in the last fifteen minutes on strong volume-who's dumping? we need some good news.
View on StockTwits ↗
Logan Howlett@OldManLoganAug 5
$CERS Get back up there Cerus, you got no bidness being under $3 with all the progress that's being made toward profitability and product expansion and all that.
View on StockTwits ↗
Easy Money@PLATINUM_TRADESBullishAug 5
$CERS There u go.. $2.40 Possible now another overnight swing winner 🥇 🥇
View on StockTwits ↗
Easy Money@PLATINUM_TRADESBullishAug 5
$CERS $2.24 Major resistance has to break for more.. Lets get that money🚨🚨
View on StockTwits ↗

Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.